Printer Friendly
The Free Library
22,728,043 articles and books

MP-1, Inc. Changes Name to Phoenix Biosciences, Inc. to Reflect Company Growth.



HOLLYWOOD, Fla. -- Phoenix Biosciences, Inc. strengthens its commitment to developing treatments for HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome  

Phoenix Biosciences, Inc., focused on developing, testing and offering affordable treatments for immune dysfunctions, with a concentration on HIV/AIDS, announced today that it has officially changed its name from MP-1, Inc. to Phoenix Biosciences, Inc. This reflects the company's growth and its continued focus on testing its compound drug PBS PBS
 in full Public Broadcasting Service

Private, nonprofit U.S. corporation of public television stations. PBS provides its member stations, which are supported by public funds and private contributions rather than by commercials, with educational, cultural,
119, which was developed as a unique approach for treating HIV/AIDS.

PBS119 takes a different approach than the current drugs used to treat HIV/AIDS. Instead of attacking the virus itself, this treatment uses the patient's own immune system to create an unacceptable environment for the virus inside the cell. In preliminary pilot tests conducted by Phoenix Biosciences, PBS119 demonstrated positive results, which provided the company with the added assurance to continue with their unique approach.

"With an increased focus on HIV/AIDS, our new name Phoenix Biosciences represents a turning point for the company," said Dr. Robert Keller, Chairman, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  and CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division.  of Phoenix Biosciences. "An estimated 40 million people are infected with HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States.  and we are committed to accelerating the process allowing us to offer a new, affordable and non-toxic treatment for HIV."

Phoenix is currently in the process of raising funds in order to conduct clinical trials. The company is determined to complete these clinical trials and gain FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 approval to begin offering patients this treatment worldwide.

About Phoenix Biosciences, Inc.

Phoenix Biosciences, Inc. is focused on developing, testing and offering affordable treatments for immune dysfunctions, with a concentration on HIV/AIDS in the last decade. The company has developed the compound drug PBS119 as a different approach for treating the HIV virus. This approach uses the patient's own immune system to create an unacceptable environment for the virus inside the cell. With headquarters in Hollywood, Florida, Phoenix Biosciences, Inc. is a privately-held biotech company owned by parent company Immune Balance Technologies, LLC (Logical Link Control) See "LANs" under data link protocol.

LLC - Logical Link Control
 (IBT (1) (Instructor Based Training) Training courses conducted by human teachers.

(2) (Internet Based Training) Training courses provided via the Internet.
). In addition, IBT owns Vit-Immune, which develops, tests and markets nutritional supplements that assist in the general well-being of people and enhances the benefits of PBS119 for those suffering from chronic immune diseases including HIV/AIDS. For more information about Phoenix Biosciences, Inc. or Vit-Immune, please email pbs@robkellermd.org or visit www.robkellermd.org
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 17, 2004
Words:377
Previous Article:TIAX Chosen by DOE for Hydrogen Storage Research Project; $1.5 million project will assess hydrogen storage technologies in an effort to make...
Next Article:Telkonet Highlights Powerline Communications at 2004 NMCI Industry Symposium.



Related Articles
Soane BioSciences Renamed ACLARA BioSciences.
Soane BioSciences Renamed ACLARA BioSciences.
Phoenix Technologies Announces Immediate Server Support for the AMD Athlon MP Processor.
SPOTLIGHT ON DUCKS.
Corporate changes: the consolidation of the life/health industry continued in 2001. (Life/Health).
BD Names Vincent A. Forlenza President of BD Biosciences.
BD Announces Record Fiscal Fourth Quarter and Full Year Revenues.
Medium density fiberboard reference guide.
Phoenix Biosciences, Inc. Issued United States Patent for the Clinical Development of PBS119 For HIV/AIDS; New patent marks first step towards...
Examine Role of Amplification Technology in Diagnostics of Infectious Diseases.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters